Wedel Christensen Jakob sold $198K of ILMN

Wedel Christensen Jakob (SVP, Strategy/Corp Development) sold 1,033 shares of ILLUMINA, INC. (ILMN) at $191.52 ($0.20M total) on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wedel Christensen Jakob
Published Aug 20, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Neutral
high confidence
Mentioned
$ILMN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential tax planning or portfolio rebalancing motives.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-20

Background

Form 4 filing reports insider transactions required by SEC.

Company-level read

Ticker impact

$ILMNNeutralHigh confidence
Context

SVP Wedel Christensen Jakob sold 1,033 Illumina shares for $197,840 via a 10b5-1 plan.

Expected impact

minimal downward pressure

Evidence & confidence

Sale amount is small relative to market cap and disclosed via pre‑arranged plan.

Market effects

None significant for genomics sector.

None.

None.

Counterpoint

Insider sale could signal confidence in long‑term outlook despite short‑term sell.

Key entities

  • Illumina, Inc.

    US‑listed genomics sequencing firm (ticker ILMN).

  • Wedel Christensen Jakob

    SVP, Strategy/Corporate Development at Illumina.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.